Compare PINE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PINE | ALLO |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.7M | 252.9M |
| IPO Year | 2019 | 2018 |
| Metric | PINE | ALLO |
|---|---|---|
| Price | $17.52 | $1.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $17.67 | $8.67 |
| AVG Volume (30 Days) | 159.5K | ★ 2.4M |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $57,423,000.00 | N/A |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $2.05 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.81 | N/A |
| 52 Week Low | $13.10 | $0.86 |
| 52 Week High | $17.88 | $3.78 |
| Indicator | PINE | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 73.34 | 61.26 |
| Support Level | $17.10 | $1.39 |
| Resistance Level | $17.54 | $1.52 |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 78.62 | 87.50 |
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.